BiotechTube

EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin

Phase 2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC

Conditions

NSCLC

Trial Timeline

Feb 6, 2024 → Dec 1, 2027

NCT ID
NCT06246110

About EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin

EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carboplatin is a phase 2 stage product being developed by Eikon Therapeutics for NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06246110. Target conditions include NSCLC.

What happened to similar drugs?

7 of 20 similar drugs in NSCLC were approved

Approved (7) Terminated (3) Active (11)
✅DurvalumabAstraZenecaApproved
✅OsimertinibAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅CrizotinibPfizerApproved
✅crizotinibPfizerApproved
✅NivolumabBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06246110Phase 2Recruiting

Competing Products

20 competing products in NSCLC

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
37
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
BBP-398 + osimertinibLianBioPhase 1
11
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
26
YH42946YuhanPhase 1/2
39
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
32
DS-1205c + OsimertinibDaiichi SankyoPhase 1
21
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
47
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
35
gilteritinibAstellas PharmaPhase 1
36
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
naquotinib + midazolamAstellas PharmaPhase 1
29
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
35
ExisulindAstellas PharmaPhase 1/2
32
naquotinibAstellas PharmaPhase 1
21
ASP8273Astellas PharmaPhase 2
27